Madrigal Pharmaceuticals, Inc. (MDGL) Earnings Call Transcript & Summary
May 6, 2026
Earnings Call Speaker Segments
Tina Ventura
executiveAppreciate that, Brilla. Hello, everyone, and thanks for being here as we go through Madrigal's results for the first quarter of 2026. A press release went out earlier today, and the slide deck that goes along with this webcast has been posted in the Investor Relations area of our site. Joining me on this call are Bill Sibold, our Chief Executive Officer; Dave Sergel, our Chief Medical Officer; and Mardi Dier, our Chief Financial Officer. Prepared remarks from them will come first, and Q&A will follow. Kindly turn to Slide 2. Certain forward-looking statements are going to be made by us today. For a discussion of the risks that could lead actual results to differ from those forward-looking statements, we point you to our SEC filings. Having said that, I'll hand things over now to Bill on Slide 3.
Bill Sibold
executiveThank you, Tina. Morning, everyone, and I appreciate you being here. We've kicked off 2026 in excellent fashion. Our strategic growth priorities — maximizing Rezdiffra's value and advancing our pipeline — have seen tremendous strides. Rezdiffra has now reached blockbuster status, with net sales exceeding $1.1 billion across the last 12 months. In a market still in its infancy, that amounts to a $1 billion run rate. Penetration remains low, diagnosis rates remain low, unmet need remains high, and the market continues expanding at a double-digit pace. Taken together, those fundamentals point to a truly remarkable growth opportunity ahead. Competition has contributed to market growth, yet not at Rezdiffra's expense. Outside of F2/F3 MASH, we're pushing forward with our F4C outcomes trial, where a label expansion could double Rezdiffra's opportunity. And since we view this as one of the most compelling opportunities in the industry, we moved fast to assemble the leading pipeline in MASH. Yesterday we added to it with a new siRNA asset targeting a mutation in the PNPLA3 gene, a genetically validated disease driver in a meaningful subset of patients. Stepping back, it's difficult to find another opportunity combining these market fundamentals with this level of product strength. We hold a first-in-disease approval, a foundational therapy, a rapidly expanding market, and we're building an industry-leading pipeline. We think Madrigal is in a really strong spot to come out on top and continue influencing where MASH is headed. First, I'll share where things stand with the Rezdiffra rollout, then Dave will take you through our pipeline and R&D approach, and Mardi will wrap things up by walking through the numbers. If you go to Slide 5 on net sales: we brought in $311 million in the first quarter of 2026, which is 127% higher than the same period last year. What this tells us is that Rezdiffra's trajectory matches — and often beats — the top-tier specialty launches we use as our yardstick. We've spent the past 2 years building the infrastructure needed to fuel Rezdiffra's expansion. We've expanded a substantial and still-growing group of prescribers, obtained first-line coverage from commercial insurers, and made Rezdiffra the cornerstone treatment for MASH. Together with Rezdiffra's distinctive characteristics and high levels of patient compliance, this execution has let us consistently grow our patient count each quarter, as Slide 6 illustrates. By the close of the first quarter, over 42,250 patients were actively taking Rezdiffra. Measured year over year, the number of patients on therapy rose 2.5x relative to the first quarter of 2025. That's a remarkable accomplishment by any measure, particularly given that this market did not exist prior to Rezdiffra's approval. This momentum speaks to the team's strong execution, the obvious unmet need in MASH, and ongoing demand from prescribers and patients alike. And here's something we shouldn't overlook — that same forward drive has continued right into Q2. On Slide 7, you can see just how fast the MASH space is growing. From the time we launched, we've observed this in the U.S. Our addressable market looks set to grow by close to 50%, going from 315,000 patients when 2023 ended to 460,000 patients by the time 2025 wraps up — every one of those being diagnosed F2/F3 people who are seen by the specialists we target. With Rezdiffra getting approved, along with additional money pouring into the field, the market has been reshaped: there's more awareness, referrals have climbed, diagnoses have increased, specialists are engaging more, and a growing number of individuals are pursuing treatment. Even with all that, this market is still in its earliest days. Only a little above 10% is the diagnosis rate, and among those 460,000 addressable patients, Rezdiffra penetration sits at just under 10%. MASH has grown quickly as a market, and what lies ahead represents a sizable opportunity. That provides us a clear route to peak sales, and in our view, no company is positioned better than Madrigal to seize it. Yet coming first in a big market that keeps growing tells only part of the story. Our leadership position exists because Rezdiffra delivers what the MASH market wants. Slide 8 is where we highlight that. Two years after launch, 3 things stand out. First, profile matters. Among approved therapies for MASH, Rezdiffra is the only one directed at the liver; it offers broad proven efficacy across every patient subtype and comes as an oral, once-daily, well-tolerated medicine requiring no titration. In a chronic disease, that profile explains a great deal about why strong persistence and deeper prescribing continue. Second, what happens in the real world matters. A drug gets approved through Pinnacle trials, but a product's success is determined by real-world experience; having treated tens of thousands of patients, the feedback we've gotten from the community has been overwhelming that Rezdiffra's efficacy keeps surpassing expectations in actual practice. Improvements span liver stiffness, liver fat, liver enzymes, LDL-cholesterol and Lp(a); that kind of real-world experience is what builds prescriber confidence and helps cement a true standard of care; and third, we've built not just a leading product but a leading MASH company. Our team is right, our model is right, and our start is right in a market we built from the ground up. We've carried out one of the industry's best launches, with our differentiated specialty model setting a high bar for anyone entering this space. And along the way, we've learned, refined and improved how we do things. We got there ahead of everyone else, and right now there are over 10 programs in our pipeline designed to keep us out front as time goes on. You can see that same leadership in the fact that this month we're attending several big medical conferences centered on hepatology, gastroenterology and endocrinology, and at those events, over 40 abstracts on Rezdiffra are being shared. One example is a poster being shown this week at DDW: close to 70% of the Rezdiffra prescribers who were surveyed reported that the drug made their patient's quality of life better, while almost 70% anticipate expanding their Rezdiffra use within the next 6 months. Then later this month, when we're at EASL in Barcelona, more data will be presented that underscores just how wide-ranging Rezdiffra's impact is. That covers a secondary analysis of the Maestro NASH and NAFLD 1 trials. It demonstrated that patients with MASH who had reductions in Lp(a) and LDL-C support the drug's potential to reduce cardiovascular risk, whether or not they were on statins at baseline. It also covers two real-world data sets showing how Rezdiffra performs in routine clinical practice. From our perspective, evidence generation gives Madrigal a strategic advantage. The more that prescribers and payers are shown about how Rezdiffra performs across clinically relevant endpoints, the more solidly it becomes established as the foundational therapy. Everything discussed so far highlights how well Rezdiffra performs in the F2-F3 match, but there's still a big opening waiting for us in well-compensated mash cirrhosis, or F4 C, which you can see on Slide 10. No therapies have been approved in this untapped market, and the need to treat is much more urgent; our view is that F4C might double Rezdiffra's opportunity, since about 245,000 patients in the U.S. are under specialist care. A trial measuring outcomes, driven by events, is running in 4, and if it reads out positively, it should support expanding into this indication as well as full approval spanning F2 to F4C. Before I let Dave walk you through what's happening with our pipeline, I want to emphasize just how unusual the opening Magical has in front of it. We were the first to launch, we got to blockbuster status fast, and we're still only at the earliest stages of building out this market. It's hard to find anything else in the industry with fundamentals that look this good. Standing on that strong footing, we're directing investment toward the coming wave of innovation so we can widen our lead and shape what MASH looks like going forward. With that, over to Dave.
Dave Soergel
executiveAppreciate that, Bill. In R&D, what we're aiming for is simple: build the leading pipeline in MASH so we can create better treatments for patients, with Rezdiffra serving as the base. Slide 11 shows how we're accomplishing this — through focused business development and disciplined clinical execution, drawing on the know-how of a team that helped pioneer modern MASH drug development. There are 4 goals behind our strategy. Goal one: produce outcomes data and secure full approval for Rezdiffra covering F2 all the way through F4C. Goal two: push forward complementary mechanisms that can be paired with Rezdiffra, giving the strongest efficacy possible across the whole MASH spectrum. Goal three: stay modality-agnostic, with the best combination regimens serving as our strategic aim. Adding siRNA assets into our pipeline recently is proof of that thinking. And goal four: apply what we've learned to craft smarter, more informative trials and deploy capital efficiently — taking more shots on goal while only moving forward programs that meet patients' needs more effectively. Delivering outcomes data in F4C is the initial pillar of this strategy, shown on Slide 12. What gives us confidence in the Maestro MASH outcomes trial comes from the 2-year open-label experience involving 122 F4C patients in our Maestro NAFLD-1 trial. To really grasp those data, you need to understand how MASH moves into cirrhosis. Clinically significant portal hypertension, or CSPH, is the key inflection point in that progression. It's the marker of the shift away from well-compensated disease and toward decompensation, the point where the most serious complications start appearing. According to the literature, patients who have CSPH experience substantially higher rates of liver-related events, and bringing down CSPH risk reduces those event rates. That's the reason the 2-year data matter so much. By year 2, 65% of patients who had CSPH at baseline had moved into lower-risk categories; we also observed favorable shifts in other biomarkers, such as liver stiffness and fibrosis-related measures. All together, these findings back Rezdiffra's potential in F4C and strengthen our confidence in the event-driven outcomes trial. The next pillar of our R&D strategy involves advancing combination therapies built around Rezdiffra, which we know works broadly across patient subtypes. Slide 13 showcases our newest addition, ARO-PNPLA3, a clinical-stage siRNA we in-licensed from Arrowhead recently; there are a couple of reasons we're particularly excited about this asset. First, PNPLA3 is a well-understood, known target for MASH, backed by extensive epidemiological and genome-wide association studies. Second, it's a clinical-stage asset with Phase I studies already completed. And third, we know Rezdiffra performs well across all patient subtypes, PNPLA3 included. That means a combo of Rezdiffra plus this asset could deliver improved efficacy for a subset of patients who are especially vulnerable because of their genetics. The PNPLA3 mutation shows up at particularly high rates among Hispanic patients. Relative to those with wild-type PNPLA3, patients homozygous for the I148M mutation of PNPLA3 face a twofold higher risk of liver-related events. Roughly 30% of F2-F3 MASH patients are homozygous carriers of the PNPLA3 mutation, which makes it a meaningful target for our development efforts. For this asset, Phase I trials are finished, and they showed 2 key points. First, within the genetically defined group of PNPLA3 homozygotes, it works selectively. Second, at the top dose, one administration lowered liver fat by as much as 46% at 12 weeks. From Maestro NASH, we understand that bigger decreases in MRI-PDFF go along with stronger fibrosis reductions with is different. So the aim here is clear. Bring together a foundational treatment, Rezdiffra, which acts broadly, plus a targeted agent that could shift more patients into a high response group and possibly boost antifibrotic efficacy through an approach tailored to genetics. Turning back to Slide 14. Over 10 programs are now part of our pipeline. Rezdiffra moves forward in 2 Phase III trials based on outcomes. The first is our F4C study, an event-driven trial anticipated to read out in 2027, and the second is the F2/F3 study, driven mainly by histology, with data anticipated in 2028; through these trials, Rezdiffra would become the first fully approved drug with outcomes data, well ahead of other competitors. Further down the pipeline for < > Stat, or D2 inhibitor, the drug-drug interaction study with resmetirom stays on schedule to start in the fourth quarter of this year, and we anticipate launching a Phase II combination study in 2027 after regulatory discussions; for MGL-2086, our oral GLP-1, the Phase I single ascending dose study stays on schedule to begin later this quarter. For ARO-PNPLA3, our next move will be to talk with regulatory authorities about the Phase II combination trial. And our 6 siRNA targets are advancing through different stages of preclinical development. Our strategy is steady. We're constructing around a foundational treatment and giving priority to mechanisms we think are complementary on mechanistic grounds and able to enhance outcomes either widely across the population or within key patient subgroups. Our aim is to make sure Madrigal is connecting with the community and advancing the science, so we're providing meaningful progress for patients. Thanks to Rezdiffra's long-term patent protection, we have the runway to invest, innovate and define the future of mash care. With that, I'll hand it over to Mardi.
Mardi Dier
executiveThanks, Dave. If you go to Slide 15, I'll walk through a summary of our financials. Net sales for the first quarter of 2026 came to $311.3 million, which is a 127% increase compared to the same period last year. So 2026 is off to a solid beginning. Like we mentioned on the previous call, these results show the usual Q1 impact from benefit plan changes in insurance reverifications, along with a step-up in gross to net tied to our commercial contracting work for first-line access. The team did a great job handling everything moving around during the quarter. We kept adding patients at a steady pace, and gross to net ended up better than we had expected. Our current expectation is that the gross to net discount will land in the mid- to high 30s for the remainder of 2026. Going forward, the business fundamentals remain strong, and as Bill mentioned, Q2 has gotten off to a great start. For the remainder of 2026, we anticipate steady patient additions and strong net sales growth. Now on to operating expenses, which include $34 million of noncash stock-based compensation expense for the quarter. Cost of sales in the first quarter of 2026 was $26.8 million, versus $4.5 million in the same period a year earlier. At this stage, cost of sales mostly consists of royalties payable to Roche. R&D expenses for the first quarter of 2026 came in at $108.7 million, compared with $44.2 million in the prior year period. That rise was mainly driven by onetime upfront business development expenses totaling $54.3 million. Just to remind everyone, the $25 million upfront payment and associated expenses for ARO-PNPLA3 will be booked in the second quarter. SG&A expenses for the first quarter of 2026 were $268.5 million, versus $167.9 million in the prior year period. The growth was mainly attributable to continued investment in commercial activities for Rezdiffra, including head count related to the endocrinology field force expansion that took place in the fourth quarter of 2025, plus marketing efforts such as our DTC campaign. Looking forward, we expect full year 2026 R&D expenses to be approximately the same as 2025, which includes the onetime upfront payments we've announced for strategic business development investments in both periods; we expect full year 2026 SG&A expenses to rise compared with 2025 as the Endo sales force annualizes while we keep supporting the Rezdiffra launch and build the foundation for our anticipated long-term growth. This includes some choppiness, with higher Q2 SG&A expenses in 2026 because of the timing of certain marketing expenses, including DTC, then studies for the rest of the year. Net loss for the first quarter of 2026 was $94.4 million, compared with $73.2 million in the prior year period. The net loss for the first quarter included onetime upfront business development expenses of $54.3 million. While we remain focused on supporting our top line growth and building our pipeline, we're also getting ready for profitability. Now let's turn to our balance sheet. Closing out Q1 of 2026, our cash, cash equivalents, restricted cash, and marketable securities totaled $817.9 million, down from $988.6 million at the close of 2025. That balance incorporates a number of quarter-specific cash outflows, among them one-time upfront payments tied to business development and the timing of API purchases meant to underpin future Rezdiffra manufacturing; given this robust cash position, we remain well capitalized to back the continued Rezdiffra launch, move multiple pipeline programs forward, and pursue ongoing business development. So, to wrap up, Slide 16 sums up what we covered this morning. Rezdiffra keeps posting remarkable commercial results, with trailing 12-month net sales now above $1.1 billion, while demand stayed robust as patient growth more than doubled versus Q1 2025. We hold the lead in a market still early in its development, yet one that has grown nearly 50% over the past 2 years. That underscores both the scale, the opportunity, and the runway still in front of us. Beyond F2-F3, we also see meaningful upside, with F4C marking a key next stage of growth in an indication that today has no approved therapies. And crucially, we aren't standing still. We're putting money into a pipeline of more than 10 programs built to capitalize on Rezdiffra's foundation and stretch our leadership across the entire MASH spectrum. All of this adds up to a company designed for durable value creation. We think Madrigal is extremely well positioned in 2026 and beyond. I'll hand the call back to Tina now and begin the Q&A session.
Tina Ventura
executiveAppreciate it, Mardi. Now we'll shift over to the question-and-answer part of this call. Brilla, if you could kindly give everyone the instructions for the Q&A session.
Prakhar Agrawal
analystNice work on the quarter. Perhaps starting with Rezdiffra — what's showing up in the 2Q numbers so far, and what do you expect for patient additions through the remainder of the year? Then, a follow-up: since < > has now been available for MASH across several quarters, are you noticing any effect on the market's rise, if there is one?
Bill Sibold
executiveAppreciate that, Prakhar. Well, when we examine the Q2 trends — I mean stepping — first off, they're excellent. I'll address that shortly. To give background, more than 42,250 patients were on drug as we left Q1, which is 2.5x growth versus the same time a year ago — truly impressive. And consider that we're at the very start of a market. Our expectation is firmly that this becomes a mega blockbuster, $1.1 billion across the last 4 quarters, and we're in a truly excellent position; so to frame how the second quarter is going, we've had a powerful beginning. That momentum is with us. Patients keep getting added at a steady pace. Perhaps the best way is to frame it around Wegovy, which you brought up too. Wegovy has now had 3/4 of launch while we've been on the market. It is getting used, though definitely not at Rezdiffra's expense. Through it, we keep steadily adding patients. You must consider that Wegovy and GLP-1s are genuinely turning into a background therapy. Actually, the majority of physicians we speak with tell us they're already taking a GLP-1 when they arrive at the office. So they arrive at the office on a GLP-1 while having F2-F3 MASH. So our profile appears extremely, extremely strong in that setting. So it is out there. We observe them, yet we aren't observing any genuine difference. And perhaps as a last proof point, as I mentioned, we had our best MBRx week during the last quarter. And when we exited April, it was our best NBRx month since launch; so we're truly thrilled about the remainder of the year; patients will keep being added steadily, exactly as we've stated from < >
Ash Verma
analystNice work on the quarter. Could you discuss how broad prescribing is at the moment? And where do you see that going? Is it reasonable to think that most prescriptions today come from gastroenterologists? When does hepatology begin contributing, given that it's a smaller patient group, and at what point do endos turn into a major source? Then regarding the 1Q new patient ad trend. Of the 36,000 new patients added, that's below what we saw in some recent quarters. We had the same pattern in last year's first quarter, with 5,000, and then it roughly doubled after that. So is the New Year insurance deductible reset mainly causing this? And what does the new patient trend look like for the remainder of the year?
Bill Sibold
executiveGreat. Thanks, Ash. I'll begin there. The Q1 adds, once again, fit within our consistent patient growth, and it's a Q1 effect. That's all it is. When you consider the Q1 effect, it hits essentially 100% of patients on therapy. And keep in mind, what we report is the count of patients on drug on the quarter's final day, correct? So patients are entering at the top, and then there are patients on drug. So that's the Q1 effect, since everybody faces it. As I mentioned in the previous question, we anticipate consistent patient additions through the remainder of the year. Q2 has begun strongly. Perhaps now on the prescriber breadth discussion. We now have more than 10,000 prescribers, which gives us ample breadth, and we keep adding new prescribers daily. Considering just physician counts, gastroenterologists exceed hepatologists by 10:1. So most prescriptions will be flowing through them. Hepatologists got off to a somewhat quicker start. They've been treating this disease longer, likely somewhat better prepared. In fact, we know they were better prepared. With the others, we had to wire the system practice by practice. Endocrinology is only now joining in. Our efforts there really began in the fourth quarter; and you should view endocrinologists as being where gastroenterologists stood roughly 2.5 years ago, right? So they've seen some match, but they hadn't truly considered it. Now they're beginning to look more actively, and we're wiring the system for each of those endocrinologists too. So we view them as becoming a truly productive specialty for us down the road. Like I mentioned, they're encountering all these individuals who are already on GLP-1s in the background, and even so, those patients continue to present with F2F3 MASH. So our view is that down the road, this turns into an important specialty area for us too.
Kripadwar Kunda
analystI want to ask something regarding the makeup of our patients. From what I recall, you said a moment ago that GLP medications will probably serve as the foundational treatment; however, earlier you'd also described how 25% of the people referred to us are taking a combination. Could you explain the way that figure has changed across the past several quarters? Additionally, certain KOL monitoring efforts—though not every one we've carried out—indicate a preference for < > in F2 cases, so it would help to know the F2 versus F3 proportion you're observing in actual practice.
Bill Sibold
executiveYeah, I appreciate that inquiry. That's correct. We're still seeing 25-plus percent of individuals using Rezdiffra who are simultaneously taking a GLP-1, and more than 50% had prior exposure. As a result, we anticipate that pattern will persist; we believe the majority of people who arrive going forward will already have had some experience with a GLP-1. Those forces appear to be established; regarding your next inquiry, what was it about?
Tina Ventura
executiveIt's still 50 to 50.
Bill Sibold
executiveAnd I realize there are folks who've figured, well, wouldn't those writing prescriptions rather take care of the F3s initially; and I believe that relates to having someone in your office who is 1 to 2 steps from cirrhosis. Would you hold off on treating an F2, without knowing the speed at which they'll move to F3 or to cirrhosis? And no, holding off isn't what you'd do. You'd decide for that person, based on what you judge their risk factors to be, and begin therapy. So what we continue to observe — and this has held fairly steady from when launch began, roughly a 50 to 50 split between F2/F3.
Ritu Baral
analystI want to ask something at a broader level about how you expect diagnostics to expand, Bill, for the remainder of this year and into the next one. Given that rival awareness campaigns for diagnostics might be losing steam as GLP-1 launches in MASH mature, do you believe it would be worth allocating additional funds toward disease awareness? And how do you weigh possibly increasing SG&A to drive top line growth against clinical development, and against your strategy for profitability? Also, if you have a moment — some client questions have come in about your thinking on full-year estimates, which I believe remain at 1.48, but with this shift in gross to net.
Bill Sibold
executiveAll right; let me begin with the diagnostic growth topic, Ritu. I appreciate the question. So look, I'd say the evidence lies in the market sizing we've observed. Over merely 2 years, the market expanded by nearly 50%, going from 315,000 addressable patients up to 460,000 addressable patients. And we believe that — and keep in mind, diagnosis moved from 1.5 million to 1.9 million. What that shows you is that a greater number of patients are receiving diagnoses; and crucially, they are arriving at the specialist offices that were being called on, so there's a chance for them to receive a Rezdiffra prescription; so I'd say our efforts — and this is where we think Novo contributed too by generating greater awareness of the disease. So I believe we've already witnessed the proof point that when you have a product, when you have more than one company, the market expands. Now regarding diagnostics specifically, what we're additionally observing is growing interest among practices in purchasing NITs and being capable of point-of-care diagnosis. And that's another favorable trend we anticipate will persist over time. So I think that will likewise help with staging of patients and then the capacity to treat and then most importantly, to monitor how patients are faring over time; so perhaps what I'll do now is hand things to Mardi to address the remaining questions.
Mardi Dier
executiveAbsolutely. Thank you, Ritu. There were several questions bundled into that, so let me work through each one. Let's begin with SG&A. Right. Obviously, our goal is to back what we believe will be a mega blockbuster brand by leveraging our sales force and commercial push, which includes the marketing campaign and DTC; we've discussed this — and we've discussed SG&A for the remainder of the year, and what you'll see is a bump in Q2 followed by a leveling off for the remainder of the year. That said, we definitely want to stay ahead of the growth and give the brand the strongest support we can. That brings up the question of gross to net for the year too. So what did that look like? On gross to net, like we mentioned, we think there's some favorability ahead for the remainder of the year. We have clearer visibility now that Q2 is behind us. Keep in mind, we — this is a brand-new brand; so each quarter gives us more clarity. This was a Q1 quarter where we examine what the different components look like. And I'd say the team did a fantastic job handling gross to net during the quarter and positioning us well for the remainder of the year. So we think we'll land in the mid- to high 30s for the remainder of the year; and I'd add that, for Q1, we were actually slightly more favorable than that, but we're in solid shape when it comes to gross to net. So that brings us to SG&A and gross to net, and what we expect for the full year. For the full year, yes. We're comfortable with the consensus figure you referenced for the full year. That sounds right, and we're also in good shape using the same comparison. So we appear to be right on track and feel positive about the remainder of the year. And the final item you raised was profitability. The way we see it, profitability, we believe, is inevitable. We're going to be a profitable company, and that's why we're getting ready for profitability now. If we look at 2026 in particular, we won't be profitable in 2026; and specifically in Q2, because of the PNPLA3 acquisition, we won't be profitable in Q2 either. Might there be other quarters where we tip into profitability, possibly, but that really hinges on our onetime spend. But past 2026, without getting into specifics, profitability is inevitable, and we're planning for that.
Yasmeen Rahimi
analystCongratulations on a solid quarter, and the update about hearing gross tomato declining is genuinely excellent, plus that was one of our favorite questions. But let's shift over to what's happening with MAESTRO. I mean, we're nearly halfway through the year. I'd really like to know when you actually start getting a clear read on how these events are progressing and how you refine the guidance. And that would also help with understanding what to expect. I realize you've made the point about looking at the event rate, and you've consistently said those are tracking. I'd love to get some color on how you're thinking about what more we might learn regarding the < > outcome, and what's coming between now and roughly the end of the year, so we can position ourselves for a really significant pipeline expansion opportunity.
Bill Sibold
executiveGreat, Yas. Thanks so much for asking that. It's a massive opportunity for us. This is an area of really high unmet need. Dave, could you — could I hand it over to you to address the specific questions, please?
Dave Soergel
executiveOkay, yes, thank you, Yas. So clearly this is a really important study for us, and like we mentioned, the events we're observing are coming in around what we had anticipated — and our expectation remains that the trial will produce results during 2027. When trials are on the smaller side like these, it can be hard to be exact, and we'd rather give you a solid sense of the timing. So once we have that level of certainty, we'll come back with an update; as of now, though, we're sticking with '27, the events are tracking as expected, and we're eager to see what comes out.
Eliana Merle
analystBill, you brought this up when you mentioned patients arriving who are already taking a GLP-1, but could you say more about what you're observing regarding use in combination with a GLP-1 in particular, perhaps the most recent information on the share of risk creation as well — and then, I suppose, how has payer coverage for combination looked since < > received the formal label for MASH?
Bill Sibold
executiveGreat. Thanks, Ellie; we continue to see roughly 25% of patients who are concurrently taking a GLP-1 alongside Rezdiffra. And our view is that this will grow. Our belief is that this is simply unavoidable. What I mean is there are really just so many patients who are taking a GLP. When it comes to access, our access is excellent. I must say. From the very first day of launch, we've had what I'd describe as even exceptional access; and as we entered 2026 with the contracting we submitted, we've kept that excellent access. I think it resembles everything else, it's a nuance. A GLP-1 may be used together with Rezdiffra when the GLP-1 is prescribed for one of the other indications for which that GLP-1 is indicated. What we haven't observed and lack solid data on is simply whether any have a double mass prescription, we don't believe payers would permit that, but they're definitely permitting a GLP-1 to be used for a different indication and then Rezdiffra being used for MASH. And based on what we're hearing increasingly from prescribers, having the combination makes sense in many respects. And of course, we believe that because of us going out and acquiring an oral GLP-1 last year, we think this is a combination that might make sense. If you remember, when we observed a weight loss greater than 5% in patients who were not taking the GLP-1 and our Maestro NASH trial, that it produced an improved effect on fibrosis for Rezdiffra. So we're going to pharmacologically induce that, so to speak, using the GLP-1. That's the hope, and that's the study that, as Dave said, or we said before, we have that Phase I study of our oral GLP-1 starting in the next weeks.
Thomas Smith
analystNice work on the quarter. Over these past 12 months, your pipelines grew a great deal, with quite a few programs. That oral benefit you achieved with the 2 inhibitor. Sounds like there's plenty of optionality there, but could you share some refreshed perspective on the clinical strategy and how you're positioning these doublet or triplet combos, and perhaps the standards you'll apply to move these programs past proof of concept. Then, could you also weigh in on your appetite for further BD deals after the recent string of them?
Bill Sibold
executiveThanks, Tom. Maybe I'll give a bit of context on how our pipeline is being thought about. And then Dave, if you could dive into the details; it comes back to this opportunity in front of us. We're right at the start of treating this disease that previously had no therapies and carries an incredibly high unmet need, the #1 cause of liver transplants for women in America, #2 for men. We hold the foundational therapy and we believe this market is truly positioned for decades of growth; we're at the front end with a foundational therapy that is really effective, and we're seeing that in the real world. Feedback has just been truly impressive from what we're hearing from prescribers that are using the product and from patients as well. When a product is already a major success and you're considering how to lead in the long run, you seize that chance. That's what we did, leaning on Rezdiffra's performance, what the market will look like going forward, and the reality that numerous companies have chosen to exit. Pfizer exits, J&J exits, BMS exits, and so on and so forth, after setbacks in some of the mining — Pfizer basically just — they simply can't move it — they weren't able to advance it. So having it with us was the better outcome. What we did was search for mechanisms of action that, in our view, would work well alongside Rezdiffra. On their own, those mechanisms might not have had sufficient strength or quality to take on the monotherapy competition. Yet combining them with Rezdiffra—yielding greater efficacy throughout the entire population or within a subpopulation—moves us toward long-term leadership. That could take the form of a fixed-dose combination when oral, or a regimen pairing a daily pill with an siRNA administered every 3 to 6 months, exactly like our arrangement with Arrowhead, which we regard as excellent. And we managed to accomplish this in a remarkably capital-efficient way. We've built a top-tier pipeline for less than $300 million. That's something you simply won't find elsewhere. In no other therapeutic area have I come across this. And since we hold a leadership position, I believe we've gained access to opportunities that likely wouldn't be a fit for others. That's the way we look at it. Certainly, across roughly the last 10 months, we've gotten a pretty substantial amount of BD done. So how hungry are we going forward? We keep looking at every single possibility out there in MASH on an ongoing basis. Any time we come across an opportunity matching a mechanism we like but don't yet have, we'd look into that opportunity and bring it in. Yet once more, consider how we've already approached this, doing so with great efficiency, and that same discipline will carry on ahead. So with that said, perhaps I'll hand things to Dave so he can address any particular details.
Dave Soergel
executiveAbsolutely, Bill — that was a really solid recap. I think the best way to frame this, like Bill was pointing out, is that we've got our foundational therapy, correct? That means Rezdiffra serves as the base we can seek out combination partners for, in order to boost efficacy and get better outcomes for patients — that's the whole concept. And the way we've gone about it is by seeking validated targets whose biology is complementary, and we don't tie ourselves to any one modality. That's how the pipeline got built. We've got small molecules, we've got siRNAs — anything that might work more effectively alongside Rezdiffra is fantastic. Now, it's key to begin with the fact that Rezdiffra also raises the bar high. As MAESTRO NASH has shown us, Rezdiffra performs very well across every subpopulation. So when we run Phase II studies, our standard for advancing products is that they need to be meaningfully capable of delivering a potential meaningful benefit to patients by the close of Phase II. But every decision we make will be driven by data. We've discussed a few different instances — take PNPLA3, for example, where we're targeting a very specific patient population: those who are homozygous for I148M, PNPLA3 mutations. Again, that's a highly prevalent mutation and highly burdensome when it comes to clinical outcome. Still, we think that with Rezdiffra as the base, adding PNPLA3 could deliver an even greater benefit for those patients. And as Bill just pointed out regarding GLP-1, that's a separate strategy, correct? Its purpose is to generate modest yet important weight loss for patients, which can drive Rezdiffra's antifibrotic effect. So in early clinical development, what we're seeking in these kinds of initial combination studies are mainly biomarkers — things like changes in MRI-PDFF — plus other biomarkers of fibrosis along with additional blood-based and imaging biomarkers, so we can make decisions on what to advance into Phase III. But that move to Phase III must be supported by data that convinces us these products will be meaningful additions to the therapeutic armamentarium, and in each instance, we believe all of these programs carry that potential.
Bill Sibold
executiveOkay, and perhaps to sharpen the point a bit more. Should a benefit appear, we push those forward quickly; should one not appear, we shut them down quickly. And that's somewhat of a — once more, another distinction here at Magical, since we aren't tied to one pipeline asset having to perform for the company to actually be something, we can be merciless when prosecuting these trials, and we will be. Should it work, wonderful. Should it not, I mean, wonderful, we move ahead, because we're already beginning with the product we possess, namely Rezdiffra, which is what makes this strategy possible.
Akash Tewari
analystManoj here, filling in for Akash. I just have one question about the master outcome baseline post show, where mean platelet count in the population sits at around 150,000. That looks lower than the roughly 180 seen in the symmetry Phase II, yet it still appears higher than the FC, the LA data you presented, which I believe was around 120,000. So in the oil data you observed roughly 2% to 3% of < > even, but considering this outcome, the baseline population platelet count is above that data. Given that platelet count difference, that mean platelet count difference, would you expect to see some difference in the even rate there?
Bill Sibold
executiveGreat. Thanks for the question. Dave, I'm going to pass it over to you.
Dave Soergel
executiveAbsolutely. Yeah, so you're pointing to something really critical here, which is that in these F4c trials, you need to make sure you're enrolling the correct patient population within that F4c group. F4c isn't one single uniform disease, correct? So for instance, patients who have only recently moved from F3 to F4 may take some time before they reach decompensation, while those who have CSPH — clinically significant portal hypertension — are right at the edge of a decompensation event, and it's those patients who are more likely to generate events in the near term. So as you're pointing out, one method for measuring clinically significant portal hypertension involves platelet counts together with liver stiffness measurements, following the Baveno criteria. And like we've discussed previously, in our — both in our open-label extension study and in MAESTRO outcomes, we've permitted patients whose platelet counts are low, meaning greater than or equal to 70,000, to enter the study. So some patients do have quite low platelet counts. And that isn't the same across every Phase III protocol, so we think our outcomes trial is enriched in exactly the right manner. So by using a range of criteria to enrich the population, we make sure we observe the outcomes as we do, and still have a chance to pull these patients back from the brink of big — right at the cusp of decompensation — and move them into a less urgent stage of their disease. So on that basis, I think if you look across the open-label extension period — open-label extension study and MAESTRO outcomes, the populations are broadly comparable. Some differences will exist simply because the sample sizes differ greatly. But the inclusion criteria are quite similar, and we're seeing rates of CS PH in both studies that give us confidence. Paul, I think we'll leave it there.
Mike DiFiore
analystCongratulations on everything you've accomplished. I've got two things. First, regarding PNPLA3 — it had been partnered before and was eventually handed back to Arrowhead. Without putting you in a position of representing J&J, could you take us through what Madrigal identified in this asset that made it appealing as of today? And what did the diligence process reveal that gave you belief in this program? Then I have one more question.
Bill Sibold
executiveGreat. Well, perhaps I'll make a broad comment, and I'll begin with that, after which I'll hand things to Dave. Numerous big pharma organizations have chosen not to pursue match, correct? Either they'd encountered setbacks, or they believed they possessed one asset, and perhaps that isn't sufficient, which differs somewhat from our situation. But Dave, I'll turn it over to you for a particular question regarding the reasons this asset excites us so much.
Dave Soergel
executiveYeah. So, Bill, you brought this up earlier, and I'd say the place to begin is that with Rezdiffra already in our hands, as we see it, bringing in something aimed at PNPLA3 might produce stronger results for patients who carry two copies of the variant. So, to go back to how we think about strategy — targets that are validated, biology that works alongside Rezdiffra, and no attachment to any single modality — why did this particular asset meet that bar? Well, first, it's a genetic target with validation behind it. PNPLA3 has solid genetic validation, plainly tied to faster progression and worsening of MASH disease as well as the appearance of liver-related events among patients who are homozygous compared with those who are wild type. Second, I'd point out the modality is proven; siRNA, as other products have shown by reaching the market, is safe and can be given once every 3 to 6 months, or even as far out as 12 months. That makes it a very appealing modality with strong tolerability. And finally, there's clinical evidence, correct? We had Phase I data from patients in which liver fat reductions showed up. So Phase I gave us a proof of concept, and just as the Maestro NASH data for Rezdiffra showed, greater liver fat reduction translates into greater efficacy for resmetirom. So once more, having these 2 mechanisms complement each other was especially convincing. For all of those reasons, then, we're adding a clinical stage asset, moving our pipeline forward, and potentially giving something to patients who genuinely need a therapy.
Bill Sibold
executiveYes. And I mean, look, liver fat went down by 46%. So I mean, from where we sit, that's pretty impressive efficacy. And let's see what happens when you put it in combination. I think it's a really exciting question to ask. And look, it's been through Phase I, right? This is an acceleration of our siRNA efforts.
Andy Chen
analystThis is Brandon here, filling in for Andy. We'd like to know whether you could put your various NASH combo candidates in ranked order — which one gets you the most excited from a clinical standpoint? Thanks for that question. I'll hand it over, and my take is that whichever candidate performs best is the one we'll favor most, or the ones that perform best. But Dave, what's your perspective on this?
Dave Soergel
executiveChoosing between our children, so to speak. I mean, they're — look, we in-licensed them. Each of these assets came in for the reasons we've discussed, since all of them could substantially shift the efficacy needle either for a subpopulation or across the wider group. Which ones we advance into Phase III programs and eventually toward registration is a decision resting on the combination data; as we've laid out, we have — since our focus is MASH and we've got experience in this area, a great deal of experience conducting clinical trials in MASH. The sites are familiar to us. We understand how to execute the trials. That means we can be efficient, get these studies done, and generate the data that lets us make that call. But like I said, the data need to be meaningfully different. So with PNPLA3, as Bill mentioned, a 46% reduction in MRI-PDFF is great. Paired with Rezdiffra, if that goes even further, pushing more patients into that super responder category, that's amazing. We'll take that program into Phase III. And the same holds for every one of these programs; so really it comes down to Phase II, and we'll advance the programs in a manner that makes sense for building the pipeline and delivering value to patients.
Jon Wolleben
analystNice work on the momentum. Bill, I believe you mentioned something regarding a route to peak sales. So I'd like to hear a bit more about how that route unfolds when it comes to timing, the length of time until you arrive there, and how large reefer might become later on?
Bill Sibold
executiveAppreciate it, Jon. You picked up on that. Look, from our perspective, this is set to become a mega blockbuster. What's the way we arrive there? We keep doing what we've been doing. Diagnosis rates are climbing; more patients are getting on drug, we're steadily adding patients, and we're building our route to feed sales. I'd say it's fairly straightforward. We simply keep up the hard work we're doing. There are plenty of patients. The market is growing, penetration rated low, and the diagnosis rate right now is low. Every one of these things is rising. So there are literally years and years and years in front of this market expanding. And like I mentioned earlier, as additional companies enter, it actually benefits us, since it fuels market expansion. Our initial focus was always on that 315,000 just who was sitting in those prescribers' offices, at the moment. Luckily now, we even have more potential with the arrival of other companies coming in and driving diagnosis, et cetera. So keep doing what we're doing, steadily add, and we'll find our route to peak.
Tina Ventura
executiveGreat. Thanks, Jon. Operator, we have time for 1 more question, please.
William Wood
analystCongratulations on a really strong quarter. When I look at your pipeline, like you mentioned, there are roughly 10 pipeline assets right now. Should we be anticipating further additions to that pipeline? If that's the case, what kind of things would you be seeking, whether that means additional oral candidates, additional siRNAs, or perhaps something we aren't even talking about here. And then regarding that go, no-go scenario, I was wondering whether any programs you've either brought in or been advancing in-house have reached that threshold you've already flagged, and maybe you could address anything that might have shifted in terms of where you're aiming going forward, or whether you're fairly satisfied with your current guidance and simply focused on execution.
Bill Sibold
executiveWilliam, I really appreciate that question. Look, we've put together what I believe is the top pipeline in NASH, and it cost us under $300 million. Once again, as I mentioned a few things, it shows plenty of people remain uninterested in this space, which works in our favor since we are interested, and we're positioned better to drive innovation thanks to our capacity to leverage Rezdiffra's foundational backbone therapy; so yes, we're continuing to look. Obviously, we've removed a good deal from consideration for what we'd pursue. But it will be heavily mechanistic-driven — is there something we find especially compelling. There remain, I'd say, a few mechanisms out there that appear compelling. After that, it comes down to locating one and locating one that can actually be transacted. So anticipate that there could be more. Absolutely, we'd love to sort of complete the pipeline, so to speak, with our — with the remaining — a few remaining mechanisms, but we're a long way through it at this point. The focus now is really on getting these into the clinic, producing data, and being able to make calls; so that's our thinking on it. But it's really, once again, within under 12 months to have gone from a single asset company, one with an extraordinarily promising future on track to become a mega blockbuster, to now, on the strength of that success, being capable of establishing that next phase of leadership, which we believe is truly long-term oriented.
Tina Ventura
executiveOkay, thank you, Bill. And thanks to you, Brilla, plus thanks to everyone for spending your time and showing interest in us today. That brings our call to an end. Roughly 2 hours from now, a replay of this webcast can be found on our website. We appreciate you being with us.
Operator
operatorThank you, everyone, for joining us on this call. At this point you're free to hang up. I hope the rest of your day is great.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Madrigal Pharmaceuticals, Inc. transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Madrigal Pharmaceuticals, Inc. earnings transcripts and 133,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Madrigal Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.